IGM Biosciences Inc expected to post a loss of $1.37 a share - Earnings Preview

IGM Biosciences

01/11/2021 13:01

* IGM Biosciences Inc  IGMS.OQ   IGMS.O  is expected to show no
change in quarterly revenue when it reports  results on November
3 (estimated). 
​* Refinitiv's mean analyst estimate for IGM Biosciences Inc is
for a loss of $1.37 per share. For the same quarter last year,
the company reported a loss of 66 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for IGM Biosciences
Inc is $101​, about 53.5% above​ its last closing price
of $46.92. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -1.19       -1.17      -1.16     Beat    0.6
 Mar. 31 2021  -0.96       -0.98      -0.95     Beat    3.1
 Dec. 31 2020  -0.71       -0.87      -0.79     Beat    9​
 Sep. 30 2020  -0.68       -0.69      -0.66     Beat    4.3
 Jun.          -0.64​      -0.64      -0.62     Beat    3.9​
 30​ 2020​                                              
 Mar. 31 2020  -0.55       -0.55      -0.58     Missed  -5.5​
 Dec. 31 2019              -0.43      -0.49     Missed  -13.3
 Sep. 30 2019  -0.82       -0.82      -2.41     Missed  -195.1
 This summary was machine generated November 1 at 13:01 GMT.  All
figures in US dollars unless otherwise stated